India raises price cap on cancer drugs to tackle shortage

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused by a sharp rise in platinum costs. The National Pharmaceutical Pricing Authority (NPPA) approved the one-time hike in public interest after supply disruptions affected hospitals across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fkU3Y9y
via IFTTT

Read More

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected to reach over 100 billion dollars by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qb8KzFm
via IFTTT

Read More

Regulators tighten GMP oversight of pharma plants

Several states have constituted dedicated multi-member teams to ensure no facility slips through the cracks before a GMP Certificate is issued, people in the know told ET. The inspections will now be applicable to all manufacturing units without exception including MSMEs, which had previously been granted a relaxation period that lapsed in January.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nCWQ6U1
via IFTTT

Read More

India needs to remain attractive for innovation-led investment: Judith Love, Novartis

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GP6dNjY
via IFTTT

Read More

US drug regulator issues import alert for drugs made at a Dabur India plant

The US Food and Drug Administration has placed Dabur India's factory on an import alert. This action follows an inspection that revealed significant issues with data integrity and factory maintenance. Critical manufacturing records were reportedly falsified. Live birds and droppings were also found in a raw material warehouse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pa87rF2
via IFTTT

Read More

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wg9noPJ
via IFTTT

Read More

Government may lift price cap on cancer drugs making them costlier by up to 50%

India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy agents, faced shortages due to rising raw material costs. The government may allow significant price increases to boost production. This move aims to prevent treatment disruptions for thousands of patients across the nation. Revised prices are expected soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TVo6ZdO
via IFTTT

Read More